Seoochre

Using big data to design clinical trials better and predict outcomes can make it commercially feasible to develop drugs for smaller patient populations. Pharmaceutical companies are looking to big data to reduce costs in research and development and manufacturing. With the explosion of health-related data in recent years, the market for artificial intelligence in drug development, valued at US$200 million in 2015, ballooned to US$700 million in 2018 and is predicted to appreciate more than US$5 billion in 2024, according to a report by big data analytics. Artificial Intelligence (AI) and big

By applying artificial intelligence (AI) and data science approaches, organisations can turn the overabundance of data from being a challenge to solve, into an opportunity. A well-designed, automated, AI-powered PV system can not only eliminate tedious and repetitive tasks but also reduce human errors and analyse massive volumes of data efficiently. This can even empower teams with predictive signal detection capabilities with insights derived from integrating disparate big data sources. Ultimately, this can enable specialists to make more informed observations and recommendations on product

There's a need consolidate natural information with computational strategies for extricating important and fitting qualities from the thousands of qualities measured. Artificial Intelligence (AI) has been connected within the sedate disclosure field for decades. Today, conventional machinelearning modelling has advanced into an assortment of unused strategies, such as combi-QSAR and crossover QSAR, and remains a prevalent approach to consider different drug-related themes. There are different drugs on the showcase and/or in clinical trials that have been outlined by computational strategies.

Controlling the industrial crystallisation process poses a significant obstacle in the production of drugs and numerous other products. Digitisation of the crystallisation process now allows for radical change by increasing process automation to control overall crystallisation. The main pillars of Pharma 4.0 are process automation, improved control strategies, data visualisation, cloud edge storage, chemometrics, and mathematical modelling technologies. SmartCrys is a revolutionary integrated process control system that harnesses the mainstays of Pharma 4.0 with the combination of PAT tools i

Artificial Intelligence (AI) and machine learning-based technologies have the potential to transform healthcare because they offer new and important insights derived from the vast amount of data generated during the delivery of healthcare every day. The capacity of AI to learn from real-world feedback and improve its performance makes this technology uniquely suited as Software as a Medical Device (SaMD) and is responsible for it being a rapidly expanding area of research and development. Clinical pharmacy practice may undergo major change due to the implementation of this technology. The cha

Soft gels, also known as soft capsules or soft caps, are a highly popular pharmaceutical and nutraceutical dosage form, with around 2,500 units consumed every second globally. A forecast by HJR Research predicts a CAGR of 5.5 per cent over the next decade, with the global market value expected to reach $756 billion by 2025. During the same period, the Asia-Pacific region is projected to be the fastest-growing market at a CAGR of 6 per cent, in terms of value. Driven by the increasing popularity of nutraceuticals, where clean label and comfort in swallowing are key factors in customer buying d

Cancer drug resistance is complex phenomenon and can be categorised as intrinsic or acquired resistance. In few cases, cancer cells survive even at the clinically relevant doses of established standard chemotherapy which is called as intrinsic resistance whereas at some instances after attaining promising result at initial phases, therapy suddenly turns out to be non-responsive and leads to recurrence of tumour growth. This acquired drug resistance often called as Multi Drug Resistance (MDR) when cancerous cells develop resistance and cross resistance to functionally or even structurally unre

Biologics are basically the products which are developed and produced from living organisms like human, plant or animal cells and, of course, microorganisms (bacteria, yeast, etc.). Having no definite structure, biologics are large and complex molecules which undergo sophisticated procedures while being developed and manufactured. Monoclonal antibodies, hormones, enzymes, insulin, etc. can be referred to as biologics.

Generics are simple molecules and exact copies of approved brand drugs. Contrary to biologics, generics are easier to synthesize, purify and manufacture. Drugs such as phenyt

However, these efforts are haunted by a shortage of resources, restrictions on importing API, social distancing at facilities, disturbed supply chains, and tremendous pressure to quickly manufacture and distribute products. Despite these arduous circumstances, it remains critical for pharma companies to maintain quality and compliance and follow regulatory guidelines. Doing so requires pertinent measures to ensure adherence to Current Good Manufacturing Practice (CGMP) guidelines, and data integrity to meet the requirements of regulators including the U.S. Food and Drug Administration (FDA),

Artificial Intelligence (AI) and machine learning-based technologies have the potential to transform healthcare because they offer new and important insights derived from the vast amount of data generated during the delivery of healthcare every day. The capacity of AI to learn from real-world feedback and improve its performance makes this technology uniquely suited as Software as a Medical Device (SaMD) and is responsible for it being a rapidly expanding area of research and development. Clinical pharmacy practice may undergo major change due to the implementation of this technology. The cha

Many Pharma companies in EU suffer a size problem. When revenues are below 100 M€ is extremely difficult to survive in a market where to renew the portfolio is increasingly costly, as well as to pay the regulatory demands, which grow year by year (environmental regulations, verification, wastes processing, plastics control, etc...). Additionally, the easy solution of playing in the Generics Market does not work anymore, mostly due to the devastating price erosion in major markets (France, Germany, Italy and Spain). These companies use to be a family property and their operations do not exceed

Biopharma’s efforts to digitally transform operations are proving more important than ever to drive improvements in process efficiency and deliver essential treatments to patients. However, the industry’s attempts are returning mixed results and the digital transformations of many enterprises remain in early-phase development. As with any business initiative, a lack of clear goals and strategies keeps some biopharma programs from being successful. As a result, these shortfalls may be further preventing many companies from moving toward the more data-driven future the industry needs to deliver

Bacterial infections are responsible for a wide spectrum of diseases in humans causing significant morbidity and mortality on a global scale. Bacteria can survive in two different forms: free-living planktonic form and biofilm form. Bacterial biofilms are densely packed communities of bacterial cells which are surrounded by a self-produced polymeric matrix. It is reported that over 80% of microbial infections including many chronic diseases in humans are associated with biofilm. Apart from causing havoc in the form of deadly diseases, biofilm bacteria can make medical implants malfunctional o

Traditional clinical trials have long served as the cornerstone of medical research, providing essential evidence for evaluating the safety and efficacy of new interventions. However, these trials often encounter significant challenges, including inefficiencies, high costs, logistical complexities, and limited participant diversity. Post the COVID-19 pandemic era, a groundbreaking approach called decentralized clinical trials (DCTs) has emerged as the new normal, harnessing technological advancements to revolutionize the landscape of medical research. This article explores the principles, key

Medicine is the testament to the virtue of human innovation - a collective desire to reduce the burden of disease and an ever evolving journey to enhance the quality of human health. The origin of medicines can be traced back to ancient times when human began to use the natural resources to treat injuries and illness. Highly developed and documented evidences of medicinal practices comes from the world’s most ancient civilisations such as Egypt, India, China and Greece1. Traditional Chinese medicine2, which dates back more than 2,500 years, used a combination of herbs, acupuncture, and other

Artificial intelligence is a field of engineering and science that focus on making intelligent machines. Artificial intelligence is a top technology that is reshaping the pharmaceutical industry's future. For ages, the pharmaceutical industry has been developing cures and treatments. Traditionally, medication design and manufacture took many years, extensive clinical studies, and sky-high prices.This has been changing with the advancement of 21st-century technology. We will see different drug designs, manufacturing, and clinical trials in the future.

Natural Language Processing (NLP), Mach

A countless number of proteins including growth factors receptors, and cytokines play a pivotal role during the onset and exacerbation of numerous human diseases including cancer, autoimmune and inflammatory disorders.1

Of these proteins, extracellular and membrane-associated proteins represent around 40% of human proteome and they play diversified roles including signal transduction, cell adhesion, cell-cell interaction, and solute transport. Accordingly, the vast majority (ca. 60%) of current therapeutic approaches; such as small molecule inhibitors, oligonucleotide agents and monoclonal

Cannabis plants contain a wide variety of complex compounds including phytocannabinoids, terpenoids and flavonoids, found mainly in the inflorescences. Major phytocannabinoids like CBD and ∆9-THC have beneficial effects on human health. It is well known that variations in their profiles are connected to growth, light quality, humidity, the use of pesticides, harvesting and especially post-harvesting, like improper drying procedures that can facilitate fungal and microbial growth. Mass spectrometry is the tool of choice for the analysis of all these biologically active compounds along with tha

The spleen is an organ found in all vertebrates. It is a large secondary lymphoid organ that primarily functions as a blood filter. The second spleen’s function is immune system surveillance. As a specialized immune organ, the spleen plays a significant role in innate and adaptive immunity. Specifically, the spleen is a crucial organ for peripheral immune tolerance, complementing central immune tolerance. Splenectomy in both study animals and humans results in overwhelming infections with especially, encapsulated bacteria [1]. On the opposite, supporting the immune system with an additional s

Human and veterinary antimicrobial misuse is one of the cornerstone drivers of antimicrobial resistance (AMR) leading to a rapidly drying up of the antibiotic pipeline. In 2010, the Indian subcontinent was adjudicated to be the world’s largest consumer of antibiotics and hence curbing injudicious use of antibiotics was a must. The current drivers of AMR include veterinary, human, biomedical waste and from innate evolutionary genetical factors leading to the genesis of the menacing MDR, XDR and PDR strains seen worldwide. High grade of evidence now underscores the necessity for antimicrobial s